Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:02 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 434 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Vascular Disorders Clear all

Conditions: Diabetic Retinopathy
Interventions: Laser Photocoagulation, Bevacizumab; Procedure · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 34
States / cities: Loma Linda, California • Palm Springs, California • Santa Barbara, California + 28 more

Conditions: Retinal Vascular Disease
Interventions: Swept-Source Optical Coherence Tomography; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetic Retinopathy
Interventions: Tarcocimab, Sham injection; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 38
States / cities: Tucson, Arizona • Fullerton, California • Glendale, California + 34 more

Conditions: Cerebral Amyloid Angiopathy
Interventions: AMDX-2011P; Drug
Lead sponsor: Amydis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Diabetic Retinopathy
Interventions: RO7663498; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: Glendale, California • Oak Forest, Illinois • Columbus, Ohio + 1 more

Conditions: Diabetic Retinopathy, Diabetes Mellitus
Interventions: Aim 3: Contract; Behavioral
Lead sponsor: Wills Eye; Other
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
Interventions: ranibizumab (Lucentis); Drug
Lead sponsor: Retina Associates of Cleveland, Inc; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetic Retinopathy
Interventions: Fenofibrate, Placebo; Drug · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 80 Years
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 66
States / cities: Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more

Conditions: Diabetic Retinopathy
Interventions: doxycycline monohydrate, Placebo; Drug
Lead sponsor: Thomas Gardner; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Coats' Disease, Idiopathic Retinal Telangiectasia, Retinal Angiomatous Proliferation, Polypoidal Choroidal Vasculopathy, Pseudoxanthoma Elasticum, Pathological Myopia, Multi-focal Choroiditis, Rubeosis Iridis, Von Hippel Lindau Disease, BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Interventions: ranibizumab injection (0.5 mg); Drug
Lead sponsor: Manhattan Eye, Ear & Throat Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: New York, New York

Conditions: Retinal Vein Occlusion, Macula Edema
Interventions: TLC399 (ProDex); Drug
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 20
States / cities: Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 16 more

Conditions: Diabetic Retinopathy
Interventions: Finerenone (BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: Not listed
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Chula Vista, California • El Centro, California • Fort Lauderdale, Florida + 7 more

Conditions: Diabetic Retinopathy, Macular Edema
Interventions: aflibercept; Drug
Lead sponsor: Rishi Singh; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions: THR-687 dose level 1, THR-687 dose level 2, THR-687 dose level 3; Drug
Lead sponsor: ThromboGenics; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 4 more

Conditions: Wet Age-related Macular Degeneration
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 50 Years and older
Enrollment: 557 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 65
States / cities: Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more

Conditions: Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
Interventions: LKA651, Sham Comparator; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 5
States / cities: Pasadena, California • Fort Myers, Florida • Miami, Florida + 2 more

Conditions: Diabetic Retinopathy
Interventions: Octreotide Acetate in Microspheres, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Moderate Non-proliferative Diabetic Retinopathy
Interventions: Alpha Lipoic Acid; Dietary Supplement
Lead sponsor: Ferris State University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 2
States / cities: Big Rapids, Michigan • Grand Rapids, Michigan

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Triamcinolone Acetonide + laser, Ranibizumab + laser, Sham injection + laser, Ranibizumab + deferred laser; Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 50
States / cities: Artesia, California • Beverly Hills, California • Irvine, California + 42 more

Conditions: Central Retinal Vein Occlusion
Interventions: aflibercept, bevacizumab; Drug
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 72
States / cities: Phoenix, Arizona • Tucson, Arizona • Mountain View, California + 60 more

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 58
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 51 more

Conditions: Neovascular (Wet) Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy
Interventions: SCD411 0.05mL (2mg); Drug
Lead sponsor: Sam Chun Dang Pharm. Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 4
States / cities: Stuart, Florida • Winter Haven, Florida • Lemont, Illinois + 1 more

Conditions: Diabetic Retinopathy (DR)
Interventions: PRONTO-EYE; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Central Retinal Vein Occlusion, Proliferative Diabetic Retinopathy
Interventions: Intravitreal Aflibercept Injection; Drug
Lead sponsor: Ophthalmic Consultants of Boston; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)

Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

A Study of AMDX-2011P in Participants With CAA

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy

Overcoming Barriers in Vision Care Utilization of African Americans With Diabetes

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

Fenofibrate for Prevention of DR Worsening

Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy

Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy

TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)

Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab

A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema

Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy

The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy

Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

Using Implementation Science to Adapt a Targeted Transportation Intervention for Patients With Diabetic Retinopathy (PRONTO-EYE)

Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion